cyc 202 has been researched along with vanoxerine in 3 studies
Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (vanoxerine) | Trials (vanoxerine) | Recent Studies (post-2010) (vanoxerine) |
---|---|---|---|---|---|
979 | 7 | 393 | 556 | 5 | 93 |
979 | 7 | 393 | 28 | 0 | 20 |
Protein | Taxonomy | cyc 202 (IC50) | vanoxerine (IC50) |
---|---|---|---|
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.46 | |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.0103 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 3.84 | |
Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.0969 | |
Small conductance calcium-activated potassium channel protein 2 | Rattus norvegicus (Norway rat) | 0.073 | |
Small conductance calcium-activated potassium channel protein 3 | Rattus norvegicus (Norway rat) | 0.073 | |
Small conductance calcium-activated potassium channel protein 1 | Rattus norvegicus (Norway rat) | 0.073 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.1485 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.022 | |
Transporter | Rattus norvegicus (Norway rat) | 0.114 | |
Mu-type opioid receptor | Homo sapiens (human) | 3.53 | |
Kappa-type opioid receptor | Homo sapiens (human) | 2.14 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
3 other study(ies) available for cyc 202 and vanoxerine
Article | Year |
---|---|
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |